SCHWERPUNKT: Myome und Endometriose

Uterusmyome in der Schwangerschaft (S. 7–12)

L. K. Platzer, S.Wallwiener, M.Wallwiener

Literatur:

1. Qidwai GI et al. Jacoby, Obstetric outcomes in women with sonographically identified uterine

leiomyomata. Obstet Gynecol 2006; 107(2 Pt 1): 376–82

2. Exacoustos C & Rosati P. Ultrasound diagnosis of uterine myomas and complications in

pregnancy. Obstet Gynecol 1993; 82(1): 97–101

3. Strobelt N. et al. Natural history of uterine leiomyomas in pregnancy. J Ultrasound Med 1994;

13(5): 399–401

4. Laughlin SK et al. Prevalence of uterine leiomyomas in the first trimester of pregnancy: an

ultrasound-screening study. Obstet Gynecol 2009; 113(3): 630–5

5. Stout MJ et al. Leiomyomas at routine second-trimester ultrasound examination and adverse

obstetric outcomes. Obstet Gynecol 2010; 116(5): 1056–63

6. Terry KL et al. Reproductive characteristics and risk of uterine leiomyomata. Fertil Steril 2010;

94(7): 2703–7

7. Guo XC & Segars JH. The impact and management of fibroids for fertility: an evidence-based

approach. Obstet Gynecol Clin North Am 2012; 39(4): 521–33

8. Laughlin SK et al. Postpartum factors and natural fibroid regression. Am J Obstet Gynecol

2011; 204(6): 496 e1–6

9. Lam, SJ. The impact of fibroid characteristics on pregnancy outcome. Am J Obstet Gynecol

2014; 211(4): 395 e1–5

10. Rice, JP et al. The clinical significance of uterine leiomyomas in pregnancy. Am J Obstet

Gynecol 1989; 160(5 Pt 1): 1212–6

11. Cooper NP & Okolo S. Fibroids in pregnancy--common but poorly understood. Obstet

Gynecol Surv 2005; 60(2): 132–8

12. Muram D. Myomas of the uterus in pregnancy: ultrasonographic follow-up. Am J Obstet

Gynecol 1980; 138(1): 16–9

13. Segars JH et al. Proceedings from the Third National Institutes of Health International

Congress on Advances in Uterine Leiomyoma Research: comprehensive review, conference summary

and future recommendations. Hum Reprod Update 2014; 20(3): 309–33

14. Parker WH. Etiology, symptomatology, and diagnosis of uterine myomas. Fertil Steril; 2007;

87(4): 725–36

15. Katz, VL. Complications of uterine leiomyomas in pregnancy. Obstet Gynecol 1989. 73(4):

593–6

16. Dildy G Aet al. Indomethacin for the treatment of symptomatic leiomyoma uteri during

pregnancy. Am J Perinatol 1992; 9(3): 185–9

17. Benson CB et al. Outcome of pregnancies in women with uterine leiomyomas identified by

sonography in the first trimester. J Clin Ultrasound 2001; 29(5): 261–4

18. Wallach EE & Vu KK. Myomata uteri and infertility. Obstet Gynecol Clin North Am 1995;

22(4): 791–9

19. Blum M. Comparative study of serum CAP activity during pregnancy in malformed and

normal uterus. J Perinat Med 1978; 6(3): 165–8

20. Klatsky PC et al. Fibroids and reproductive outcomes: a systematic literature review from

conception to delivery. Am J Obstet Gynecol 2008; 198(4): 357–66

21. Girault A et al. Leiomyomatous uterus and preterm birth: an exposed/unexposed

monocentric cohort study. Am J Obstet Gynecol 2018; 219(4): 410 e1–410

22. Coronado GD et al. Complications in pregnancy, labor, and delivery with uterine leiomyomas:

a population-based study. Obstet Gynecol 2000. 95(5): 764–9

23. Winer-Muram HT. Uterine myomas in pregnancy. J Can Assoc Radiol 1984. 35(2): 168–70

24. Vergani P et al. Do uterine leiomyomas influence pregnancy outcome? Am J Perinatol, 1994;

11(5): 356–8

25. Sheiner E et al. Higher rates of tachysystole among patients with clinically apparent uterine

leiomyomas. Am J Obstet Gynecol 2004. 191(3): 945–8

26. Szamatowicz J et al. Fibromyomas and uterine contractions. Acta Obstet Gynecol Scand,

1997; 76(10): 973–6

27. Roberts WE et al. The impact of leiomyomas on pregnancy. Aust N Z J Obstet Gynaecol 1999;

39(1): 43–7

28. Graham JM et al. Limb reduction anomalies and early in utero limb compression. J Pediatr

1980. 96(6): 1052–6

29. Romero R et al. Fetal head deformation and congenital torticollis associated with a uterine

tumor. Am J Obstet Gynecol 1981; 141(7): 839–40

30. Matsunaga E & Shiota K, Ectopic pregnancy and myoma uteri: teratogenic effects and

maternal characteristics. Teratology 1980; 21(1): 61–9

31. Daniel S et al. Fetal exposure to nonsteroidal anti-inflammatory drugs and spontaneous

abortions. CMAJ 2014. 186(5): E177–82

32. Kwon SY et al. Management of severely painful uterine leiomyoma in a pregnant woman with

epidural block using a subcutaneous injection port. Acta Obstet Gynecol Scand 2014; 93(8): 839

33. Moridaira T et al. A case of continuous epidural anesthesia for pain relief in a pregnant

woman with uterine myoma in the second trimester of pregnancy. Masui 2013; 62(10): 1253–6

34. Tropeano G et al. Non-surgical management of uterine fibroids. Human Reproduction Update

2008. 14(3): 259–74

35. Walker WJ & McDowell SJ, Pregnancy after uterine artery embolization for leiomyomata: a

series of 56 completed pregnancies. American Journal of Obstetrics and Gynecology 2006; 195(5):

1266–71

36. Mara M et al. Midterm clinical and first reproductive results of a randomized controlled trial

comparing uterine fibroid embolization and myomectomy. Cardiovascular and Interventional

Radiology 2008; 31(1): 73–85

37. Goldberg J & Pereira L. Pregnancy outcomes following treatment for fibroids: uterine fibroid

embolization versus laparoscopic myomectomy. Current Opinion in Obstetrics and Gynecology 2006.

18(4): 402–6

38. Pron G et al. Pregnancy after uterine artery embolization for leiomyomata: the Ontario

multicenter trial. Obstetrics and Gynecology 2005. 105(1): 67–76

39. Pergialiotis V et al. Perioperative Complications of Cesarean Delivery Myomectomy: A Meta-

analysis. Obstet Gynecol 2017; 130(6): 1295–1303

40. Leach K et al. First trimester myomectomy as an alternative to termination of pregnancy in a

woman with a symptomatic uterine leiomyoma: a case report. J Med Case Rep 2011; 5(1): 571

41. De Carolis S et al. Uterine myomectomy in pregnant women. Fetal Diagn Ther 2001; 16(2):

116–9

42. Tower AM & Cronin B. Myomectomy after a vaginal delivery to treat postpartum hemorrhage

resulting from an intracavitary leiomyoma. Obstet Gynecol 2015; 125(5): 1110–3

43. Tian J & Hu W. Cervical leiomyomas in pregnancy: report of 17 cases. Aust N Z J Obstet

Gynaecol 2012; 52(3): 258–61

44. ACOG Committee Opinion No. 764: Medically Indicated Late-Preterm and Early-Term

Deliveries. Obstet Gynecol 2019; 133(2): e151–e155

Grüntee in der Frauenheilkunde (S. 14–17)

J. Huber

Literatur:

1. Baxter, GJ et al. Salicylic acid in soups prepared from organically and non-organically grown

vegetables. European journal of nutrition 2001; 40(6): 289–292

2. Na, HK & Surh YJ. Modulation of Nrf2-mediated antioxidant and detoxifying enzyme induction by

the green tea polyphenol EGCG. Food and Chemical Toxicology 2008; 46(4): 1271–1278

3. Ahn WS et al. Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical

lesions. European journal of cancer prevention 2003; 12(5): 383–390

4. Zhang W et al. Tea intake and risk of oral, pharyngeal, and laryngeal carcinoma: a meta-analysis.

Medical science monitor: international medical journal of experimental and clinical research 2014;

20, 2142

5. Min NY et al. Selective death of cancer cells by preferential induction of reactive oxygen species in

response to (-)-epigallocatechin-3-gallate. Biochemical and biophysical research communications

2012; 421(1): 91–97

6. Gianfredi V et al. Sulforaphane and epigallocatechin gallate restore estrogen receptor Expression

by modulating epigenetic events in the breast cancer cell line MDA-MB-231: a systematic review and

meta-analysis. Lifestyle Genomics 2017; 10(3–4): 126–135

7. Rafieian-Kopaei M & Movahedi M. Breast cancer chemopreventive and chemotherapeutic effects

of Camellia Sinensis (green tea): an updated review. Electronic physician 2017; 9(2): 3838

8. Zhou Q et al. Green tea, black tea consumption and risk of endometrial cancer: a systematic review

and meta-analysis. Archives of gynecology and obstetrics 2016; 293(1): 143–155

9. Laschke MW et al. Epigallocatechin-3-gallate inhibits estrogen-induced activation of endometrial

cells in vitro and causes regression of endometriotic lesions in vivo. Human Reproduction 2008;

23(10): 2308–2318

10. Zhang D et al. Antiproliferative and proapoptotic effects of epigallocatechin gallate on human

leiomyoma cells. Fertility and sterility 2010, 94(5), 1887–1893

11. Ciebiera M et al.Alternative oral agents in prophylaxis and therapy of uterine fibroids—an up-to-

date review. International journal of molecular sciences 2017; 18(12): 2586

12. Guo M et al. Tea consumption may decrease the risk of osteoporosis: an updated meta-analysis

of observational studies. Nutrition Research 2017; 42, 1–10

13. Vázquez LC. Effects of green tea and its epigallocatechin (EGCG) content on body weight and fat

mass in humans: a systematic review. Nutr Hosp 2017; 34(3): 731–737. doi: 10.20960/nh.753

14. Liu YC. Modulation effect of tea consumption on gut microbiota. Applied Microbiology and

Biotechnology 2020; 104(3): 981–987

15. Wang S. Novel insights of dietary polyphenols and obesity. The Journal of nutritional biochemistry

2014, 25(1), 1–18

Operative Therapie der tief infiltrierenden Endometriose: eine Übersicht (S. 18–23)

R.Schmädecker, U. A. Ulrich

Literatur:

1. Reich H et al. Laparoscopic treatment of cul-de-sac obliteration secondary to retrocervical deep

fibrotic endometriosis. J Reprod Med 1991 Jul; 36(7): 516–22

2. Koninckx PR & Martin D. Treatment of deeply infiltrating endometriosis.

Curr Opin Obstet Gynecol 1994 Jun; 6(3): 231–41

3. Akladios C al. Is ileostomy always necessary following rectal resection for deep infiltrating

endometriosis? J Minim Invasive Gynecol 2015; 22(1): 103–9

4. Coccia ME & Rizzello F. Ultrasonographic staging: a new staging system for deep endometriosis.

Ann N Y Acad Sci 20111221: 61–9

5. Wolthuis AM et al. Bowel endometriosis: colorectal surgeon’s perspective in a multidisciplinary

surgical team. World J Gastroenterol 2014; 20(42): 15616–23

6. Wustlich M. Laparoskopisch-assistierte Sigmasegmentresektion bei Endometriose mit

Darmbeteiligung. Leipzig: Universität; 2002

7. Keckstein J et al. ENZIAN-Klassifikation der tief infiltrierenden Endometriose. Zentralbl Gynäkol

2003; 125: 291

8. Ulrich U et al. National German Guideline (S2k): Guideline for the diagnostic and treatment of

endometriosis: Long Version – AWMF Registry No. 015-045. Geburtshilfe Frauenheilkd 2014; 74(12):

1104–18

9. Ebert AD et al. Implementation of Certified Endometriosis Centers: 5-Year Experience in German-

Speaking Europe. Gynecol Obstet Invest 2013; 76 (1): 4–9

10. Hudelist G et al. Diagnostic accuracy of transvaginal ultrasound for non-invasive diagnosis of

bowel endometriosis: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2011; 37(3):

257–63

11. Jacobson TZ et al. Laparoscopic surgery for pelvic pain associated with endometriosis. Cochrane

Database Syst Rev 2009; (4): CD001300

12. Abrão MS et al. Deep endometriosis infiltrating the recto-sigmoid: critical factors to consider

before management. Hum Reprod Update 2015; 21(3): 329–39

13. Kavallaris A et al. Laparoscopic nerve-sparing surgery of deep infiltrating endometriosis:

description of the technique and patients' outcome. Arch Gynecol Obstet. 2011; 284(1): 131–5

14. Ceccaroni M et al. Laparoscopic nerve-sparing transperitoneal approach for endometriosis

infiltrating the pelvic wall and somatic nerves: anatomical considerations and surgical technique.

Surg Radiol Anat 2010; 32(6): 601–4

15. Volpi E et al. Laparoscopic identification of pelvic nerves in patients with deep infiltrating

endometriosis. Surg Endosc 2004; 18(7): 1109–12

16. Alborzi S et al. A prospective, randomized study comparing laparoscopic ovarian cystectomy

versus fenestration and coagulation in patients with endometriomas. Fertil Steril 2004; 82(6): 1633–7

17. Hart RJ. Excisional surgery versus ablative surgery for ovarian endometriomata. Cochrane

Database Syst Rev 2008; (2) :CD004992

18. Donnez O & Roman H. Choosing the right surgical technique for deep endometriosis: shaving, disc

excision, or bowel resection? Fertil Steril. 2017; 108(6): 931–942

19. Maccagnano C et al. Ureteral endometriosis: proposal for a diagnostic and therapeutic algorithm

with a review of the literature. Urol Int 2013; 91(1): 1–9

20. Barra F et al. Ureteral endometriosis: a systematic review of epidemiology, pathogenesis,

diagnosis, treatment, risk of malignant transformation and fertility. Hum Reprod Update 2018; 24(6)

:710–730

21. Nezhat C et al. Multidisciplinary treatment for thoracic and abdominopelvic endometriosis. JSLS

2014; 18(3). pii: e2014.00312.

22. Roman H et al. Laparoscopic management of diaphragmatic endometriosis by three different

approaches. Fertil Steril 2016; 106(2): e1

23. Riiskjær M et al. Bowel Endometriosis Syndrome: a new scoring system for pelvic organ

dysfunction and quality of life. Hum Reprod 2017; 32(9): 1812–1818

24. Turco LC et al. Long-term evaluation of quality of life and gastrointestinal well-being after

segmental colo-rectal resection for deep infiltrating endometriosis (ENDO-RESECT QoL). Arch

Gynecol Obstet 2019. doi: 10.1007/s00404-019-05382-8

Endometriose und Infertilität – Ätiologie, Pathomechanismen und

Paradigmenwechsel in der Kinderwunschtherapie (S. 24–32)

M. Murtinger, B. Wirleitner, A. Damko, M. Schuff , F. Kentros, J. Okhowat, D. Spitzer

Literatur:

1. Zegers-Hochschild F et al. The International Glossary on Infertility and Fertility Care, 2017.

Hum Reprod 2017;32: 1786–1801

2. Shroen D: Disputatio Inauguralis Medica de Ulceribus Ulceri. 1690

3. Dunselman GA et al. ESHRE guideline: management of women with endometriosis. Hum

Reprod 2014; 29: 400–12

4. Johnston Taylor S. Underfunded, But Undeterred: Women Raise Money for Endometriosis

Research. Endometriosis Foundation of America 2018. (https://www.endofound.org/underfunded-

not-undeterred-women-raise-money-for-endometriosis-research). Zugegriffen: 15.01.2020

5. Sutton C & Jones K. Endometriosis. Cambridge University Press 2014; 1–8

6. Leyendecker G et al. The pathophysiology of endometriosis and adenomyosis: tissue injury

and repair. Arch Gynecol Obstet 2009; 280: 529–38

7. Saha R et al. Heritability of endometriosis. Fertil Steril 2015; 104: 947–952

8. Bougie O et al. Influence of race/ethnicity on prevalence and presentation of

endometriosis: a systematic review and meta-analysis. BJOG 2019; 126: 1104–1115

9. Fung JN & Montgomery GW. Genetics of endometriosis: State of the art on genetic risk

factors for endometriosis. Best Pract Res Clin Obstet Gynaecol 2018; 50: 61–71

10. Exacoustos C et al. Isolated Ovarian Endometrioma: A History Between Myth and Reality. J

Minim Invasive Gynecol 2018; 25: 884–891

11. Vercellini P et al. Is cystic ovarian endometriosis an asymmetric disease? Br J Obstet

Gynaecol 1998; 105: 1018–21

12. Gordts S et al. Pathogenesis of deep endometriosis. Fertil Steril 2017; 108: 872–885

13. American Society for Reproductive Medicine. Revised American Society for Reproductive

Medicine classification of endometriosis: 1996. Fertil Steril 1997; 67: 817–21

14. Mettler L & Semm K. Three step medical and surgical treatment of endometriosis. Ir J Med

Sci 1983; 152 Suppl 2: 26–8

15. Klugsberger B et al. Clinical Outcome after Colonic Resection in Women with Endometriosis

Biomed Res Int 2015; 2015: 514383

16. Adamson GD & Pasta DJ. Endometriosis fertility index: the new, validated endometriosis

staging system. Fertil Steril 2010 ;94: 1609–15

17. Buchweitz O et al. Interobserver variability in the diagnosis of minimal and mild

endometriosis. Eur J Obstet Gynecol Reprod Biol 2005; 122: 213–217

18. Kennedy S et al. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum

Reprod 2005; 20: 2698–704

19. Nnoaham KE et al. Impact of endometriosis on quality of life and work productivity: a

multicenter study across ten countries. Fertil Steril 2011; 96: 366–373.e8.

20. Leyendecker G & Kunz A. Endometriose und Adenomyose. Zentralbl Gynakol 2005; 127:

288–294

21. Hamdan M et al. The impact of endometrioma on IVF/ICSI outcomes: a systematic review

and meta-analysis. Hum Reprod Update 2015; 21: 809–825

22. Muzii L et al. Antimüllerian Hormone Is Reduced in the Presence of Ovarian

Endometriomas: A Systematic Review and Meta-Analysis. Fertil Steril 2018; 110: 932–940

23. Yang C et al. Impact of ovarian endometrioma on ovarian responsiveness and IVF: a

systematic review and meta-analysis. Reprod Biomed Online 2015; 31: 9–19

24. Yılmaz Hanege B et al. Endometrioma and ovarian reserve: effects of endometriomata per

se and its surgical treatment on the ovarian reserve. Facts Views Vis Obgyn 2019; 11: 151–157

25. Harb HM et al. The effect of endometriosis on in vitro fertilisation outcome: a systematic

review and meta-analysis. BJOG 2013; 120: 1308–20

26. Borges E Jr et al. Endometriosis Affects Oocyte Morphology in Intracytoplasmic Sperm

Injection Cycles? JBRA Assist Reprod 2015; 19: 235–240

27. Shebl O et al. Oocyte competence in in vitro fertilization and intracytoplasmic sperm

injection patients suffering from endometriosis and its possible association with subsequent

treatment outcome: a matched case-control study. Acta Obstet Gynecol Scand 2017; 96: 736–744

28. Garrido N et al. The endometrium versus embryonic quality in endometriosis-related

infertility. Hum Reprod Update 2002; 8: 95–103

29. Kasapoglu I et al. Detrimental effects of endometriosis on oocyte morphology in

intracytoplasmic sperm injection cycles: a retrospective cohort study. Gynecol Endocrinol 2018; 34:

206–211

30. Shahine LK et al. Embryo quality before and after surgical treatment of endometriosis in

infertile patients. J Assist Reprod Genet 2009; 26: 69–73

31. Xu B et al. Oocyte quality is decreased in women with minimal or mild endometriosis. Sci

Rep 2015; 5: 10779

32. Demirel C et al. The Presence of Endometrioma Does Not Impair Time-Lapse Morphokinetic

Parameters and Quality of Embryos: A Study On Sibling Oocytes. Reprod Sci 2016; 23: 1053–7

33. Freis A et al. Relative Morphokinetics Assessed by Time-Lapse Imaging Are Altered in

Embryos From Patients With Endometriosis. Reprod Sci 2018; 25: 1279–1285

34. Yong PJ et al. Endometriosis and Ectopic Pregnancy: A Meta-analysis. J Minim Invasive

Gynecol pii: S1553-4650(19)31205-1.

35. Leyendecker G et al. The pathophysiology of endometriosis and adeno-myosis: tissue injury

and repair. Archives of gynecology and obstetrics 2009; 280: 529–38

36. Lessey BA & Kim JJ. Endometrial receptivity in the eutopic endometrium of women with

endometriosis: it is affected, and let me show you why. Fertil Steril 2017; 108: 19–27

37. Miravet-Valenciano J et al. Endometrial receptivity in eutopic endometrium in patients

with endometriosis: it is not affected, and let me show you why. Fertil Steril 2017; 108: 28–31

38. Jana SK et al. HOXA-11 mediated dysregulation of matrix remodeling during implantation

window in women with endometriosis. J Assist Reprod Genet 2013; 30: 1505–1512

39. Schmitz CR et al. Alterations in expression of endometrial milk fat globule-EGF factor 8

(MFG-E8) and leukemia inhibitory factor (LIF) in patients with infertility and endometriosis. JBRA

Assist Reprod 2017; 21: 313–320

40. Chen I et al. Association between surgically diagnosed endometriosis and adverse

pregnancy outcomes. Fertil Steril 2018; 109: 142–147

41. Younes G & Tulandi T. Effects of adenomyosis on in vitro fertilization treatment outcomes:

a meta-analysis. Fertil Steril 2017; 108: 483–490.e3

42. Barbosa MA et al. Impact of endometriosis and its staging on assisted reproduction

outcome: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2014; 44: 261–78

43. Arbeitsgruppe „Leitlinie für die Diagnostik und Therapie der Endometriose“ der Deutschen,

Österreichischen, Schweizerischen und Tschechischen Gesellschaften für Gynäkologie und

Geburtshilfe unter Mitarbeit der Stiftung Endometrioseforschung (SEF) und der Europäischen

Endometriose Liga (EEL). Diagnostik und Therapie der Endometriose. AWMF Nr.: 015/045. 2013

44. Schweppe KJ. Therapie der Endometriose unter Berücksichtigung der Aktivitätsgrade. Der

Gynäkologe. 2002; 35: 255–261

45. Elizur SE et al. Cryopreservation of oocytes in a young woman with severe and

symptomatic endometriosis: a new indication for fertility preservation. Fertil Steril 2009; 91:

293.e1-293.e3

Zusatzthema: Wechseljahrsbeschwerden

Phytopharmaka bei Wechseljahrsbeschwerden: Wirksamkeit und Nutzen-Risiko-

Abwägung (S. 33–39)

K. Jenett-Siems

Literatur:

1. Boblitz N. Therapie klimakterischer Beschwerden mit Cimicifuga racemosa: Erkenntnisse zu Wirkung und Wirksamkeit. J

Menopause 2002; 9: 20–25

2. Wuttke W, Seidlová-Wuttke D, Gorkow C. The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind

placebo-controlled study: effects on menopause symptoms and bone markers. Maturitas 2003; 44: 67–77

3. Wuttke W, Raus K, Gorkow C. Efficacy and tolerability of the Black cohosh (Actaea racemosa) ethanolic extract BNO 1055 on

climacteric complaints: A double-blind, placebo- and conjugated estrogens-controlled study. Maturitas 2006; 55S: 83–91

4. Osmers R, Friede M, Liske E, Schnitker J, Freudenstein J, Henneicke-von Zepelin HH. Efficacy and safety of isopropanolic

black cohosh extract for climacteric symptoms. Obstet Gynecol 2005; 105: 1074–1083

5. Frei-Kleiner S, Schaffner W, Rahlfs VW, Bodmer C, Birkhäuser M. Cimicifuga racemosa dried ethanolic extract in menopausal

disorders: a double-blind placebo-controlled clinical trial. Maturitas 2005; 51: 397–404

6. Schellenberg R, Saller R, Hess L, Melzer J, Zimmermann C, Drewe J, et al. Dose-Dependent Effects of the Cimicifuga racemosa

Extract Ze 450 in the Treatment of Climacteric Complaints: A Randomized, Placebo-Controlled Study. Evid Based Complement

Alternat Med 2012; 2012: 260301

7. Newton KM, Reed SD, LaCroix AZ, Grothaus LC, Ehrlich K, Guiltinan J. Treatment of vasomotor symptoms of menopause with

black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med 2006; 145: 869–879

8. Geller SE, Shulman LP, van Breemen RB, Banuvar S, Zhou Y, Epstein G, et al. Safety and efficacy of black cohosh and red

clover for the management of vasomotor symptoms: a randomized controlled trial. Menopause 2009; 16: 1156–1166

9. Pockaj BA, Loprinzi CL, Sloan JA, Novotny PJ, Barton DL, Hagenmaier A, et al. Pilot evaluation of black cohosh for the treatment

of hot flashes in women. Cancer Invest 2004; 22: 515–521

10. Pockaj BA, Gallagher JG, Loprinzi CL, Stella PJ, Barton DL, Sloan JA, et al. Phase III doubleblind, randomized, placebo-

controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1. J Clin Oncol 2006; 24:

2836–2841

11. Jacobson JS, Troxel AB, Evans J, Klaus L, Vahdat L, Kinne D, et al. Randomized trial of black cohosh for the treatment of hot

flashes among women with a history of breast cancer. J Clin Oncol 2001; 19: 2739–2745

12. Tanmahasamut P, Vichinsartvichai P, Rattanachaiyanont M, Techatraisak K, Dangrat C, Sardod P. Cimicifuga racemosa extract

for relieving menopausal symptoms: a randomized controlled trial. Climacteric 2015; 18: 79–85

13. Shahnazi M, Nahaee J, Mohammad-Alizadeh-Charandabi S, Bayatipayan S. Effect of black cohosh (cimicifuga racemosa) on

vasomotor symptoms in postmenopausal women: a randomized clinical trial. J Caring Sci 2013; 2: 105–113

14. Uebelhack R, Blohmer JU, Graubaum HJ, Busch R, Gruenwald J, Wernecke KD. Black cohosh and St. John’s wort for

climacteric complaints: a randomized trial. Obstet Gynecol 2006; 107: 247–255

15. Chung DJ, Kim HY, Park KH, Jeong KA, Lee SK, Lee YI, et al. Black cohosh and St. John’s wort (GYNO-Plus) for climacteric

symptoms. Yonsei Med J 2007; 48: 289–294

16. Leach MJ, Moore V. Black cohosh (Cimicifuga spp.) for menopausal symptoms. Cochrane Database Syst Rev 2012; 9:

CD007244

17. Franco OH, Cowdhury R, Troup J, Voortman T, Kunutsor S, Kavousi M, et al. Use of Plant-Based Therapies and Menopausal

Symptoms: A Systematic Review and Meta-analysis. JAMA 2016; 315: 2554–2563

18. Laakmann E, Grajecki D, Doege K, zu Eulenburg C, Buhling KJ. Efficacy of Cimicifuga racemosa, Hypericum perforatum and

Agnus castus in the treatment of climacteric complaints: a systematic review. Gynecol Endocrinol 2012; 28: 703–709

19. Beer AM, Neff A. Differentiated evaluation of extract-specific evidence on Cimicifuga racemosa’s efficacy and safety for

climacteric complaints. Evid Based Complement Alternat Med 2013; 2013: 860602

20. Teschke R. Black cohosh and suspected hepatotoxicity: inconsistencies, confounding variables, and prospective use of a

diagnostic causality algorithm: a critical review. Menopause 2010; 17: 426–440

21. Naser B, Schnitker J, Minkin MJ, de Arriba SG, Nolte KU, Osmers R. Suspected black cohosh hepatotoxicity: no evidence by meta-

analysis of randomized controlled clinical trials for isopropanolic black cohosh extract. Menopause 2011; 18: 366–375

22. Fritz H, Seely D, McGowan J, Skidmore B, Fernandes R, Kennedy DA, et al. Black cohosh and breast cancer: a systematic

review. Integr Cancer Ther 2014; 13: 12–29

23. Vollmer G, Papke A, Zierau O. Treatment of menopausal symptoms by an extract from the roots of rhapontic rhubarb: the role

of estrogen receptors. Chin Med 2010; 5: 7

24. Wober J, Möller F, Richter T, Unger C, Weigt C, Jandausch A, et al. Activation of estrogen receptor-beta by a special extract of

Rheum rhaponticum (ERr 731), its aglycones and structurally related compounds. J Steroid Biochem Mol Biol 2007; 107: 191–

201

25. Möller F, Zierau O, Jandausch A, Rettenberger R, Kaszkin-Bettag M, Vollmer G. Subtype-specific activation of estrogen

receptors by a special extract of Rheum rhaponticum (ERr 731), its aglycones and structurally related compounds in U2OS

human osteosarcoma cells. Phytomedicine 2007; 14: 716–726

26. Heger M, Ventskovskiy BM, Borzenko I, Kneis KC, Rettenberger R, Kaszkin-Bettag M, et al. Efficacy and safety of a special extract

of Rheum rhaponticum (ERr731) in perimenopausal women with climacteric complaints: a 12 week randomized, doubleblind,

placebo-controlled trial. Menopause 2006; 13: 744–759

27. Kaszkin-Bettag M, Ventskovskiy BM, Kravchenko A, Rettenberger R, Richardson A, Heger PW, et al. The special extract ERr

731 of the roots of Rheum rhaponticum decreases anxiety and improves health state and general well-being in perimenopausal

women. Menopause 2007; 14: 270–283

28. Kaszkin-Bettag M, Ventskovskiy B, Solskyy S, Beck S, Hasper I, Kravchenko A, et al. Confirmation of the efficacy of ERr 731

in perimenopausal women with menopausal symptoms. Altern Ther Health Med 2009; 15: 24–34.

29. Kaszkin-Bettag M, Beck S, Richardson A, Heger PW, Beer AM. Efficacy of the special extract ERr 731 from rhapontic rhubarb

for menopausal complaints: a 6-month open observational study. Altern Ther Health Med 2008; 14: 32–38

30. Hasper I, Ventskovskiy BM, Rettenberger R, Heger PW, Riley DS, Kaszkin-Bettag M. Long-term efficacy and safety of the

special extract ERr 731 of Rheum rhaponticum in perimenopausal women with climacteric complaints. Menopause 2009; 16:

117–131

Korasion

Endometriose in der Adoleszenz (S. 40–43)

N. Frumkin, R. Isermann, R. Schmädecker, U. A. Ulrich

Literatur:

1. Nnoaham KE et al. Impact of endometriosis on quality of life and work productivity: a multicenter

study across ten countries. Fertil Steril 2011; 96: 366–73

2. Soliman AM et al. “Factors associated with time to endometrioses diagnosis in the United States” J

Womens Health (Larchmt) 2017; 26: 788–97

3. Janssen E et al. Prevalence of endometriosis diagnosed by laparoscopy in adolescents with

dysmenorrhea or chronic pelvic pain: a systematic review Hum Reprod Update 2013; 19:570–82

4. Laufer MR et al. Prevalence of Endometriosis in Adolescent Girls With Chronic Pelvic Pain Not

Responding to Conventional Therapy. J Pediatr Adolesc Gynecol 1997; 10: 199–202

5. Sampson, J. The development of the implantation theory for the origin of peritoneal

endometriosis. Am. J. Obstet Gynecol 1940; 40: 549–557

6. Brosens I et al. Neonatal uterine bleeding as antecedent of pelvic endometriosis. Hum Reprod

2013; 28: 2893–7

7. Meyer R. Über den Stand der Frage der Adenomyositis und Adenome im allgemeinen und

insbesondere über Adenomyositis seroepithelialis und Adenomyometritis sarcomatosa. Zbl Gynäkol

1919; 43: 745–50

8. von Recklinghausen F. Adenomyomas and cystadenomas of the wall of the uterus and tube: their

origin as remnants of the wolffian body. Wien Klin Wochenschr 1896; 8: 530

9. Leyendecker G et al. Die Archimetra als neues morphologisch-funktionelles Konzept des Uterus

sowie als Ort der Primärerkrankung bei Endometriose. Repro Med 1999; 15: 356–71

10. Sampson J. The escape of foreign material from the uterine cavity into the uterine veins.” Am J

Obstet Gynecol 1918; 78: 161–175

11. Ochsenbein N & Mueller M. Endometriose: Pathogenese, Symptomatik und Diagnostik.

Gynäkologie 2006; 03: 5–8

12. Sampson J. Metastatic or embolic endometriosis due to the menstrual dissemination of

endometrial tissue into the venous circulation. Am. J. Pathology 1927; 3: 93–110

13. Mueller M. et al.: 2,3,7,8-Tetra-chlorodibenzo-p-dioxin increases glycodelin gene and protein

expression in human endometrium. J Clin Endocrinol Metab 2005; 90: 4809–4815

14. Dun EC et al. Endometriosis in adolescents“ JSLS 2015; 19, e2015.00019

15. Marsh EE, Laufer MR. Endometriosis in premenarcheal girls who do not have an associated

obstructive anomaly. Fertil Steril 2005; 83: 758–760

16. Stuparich M, Donnellan N, Sanfilippo J. Endometriosis in the Adolescent Patient. Semin Reprod

Med. 2017; 35: 102–109

17. Matalliotakis M et al. Endometriosis in Adolescent and Young Girls: Report on a Series of 55

Cases. J Pediatr Adolesc Gynecol 2017; 30: 568–570

18. Hickey M & Balen A. Menstrual disorders in adolescence: investigation and management. Hum

Reprod Update 2003; 9: 493–504

19. Smorgick N et al. Advanced Stage Endometriosis in Adolescents and Young Women. J Pediatr

Adolesc Gynecol 2014, 27: 320–23

20. Schuster M & Mackeen D. Fetal endometriosis: a case report. Fertil Steril 2015; 103: 160–3

21. Marsh CA et al. Uterine remnants and pelvic pain in females with Mayer-Rokitansky-Küster-

Hauser syndrome. J Pediatr Adolesc Gynecol. 2013; 26: 199–202

22. De Sanctis V et al. Primary Dysmenorrhea in Adolescents: Prevalence, Impact and Recent

Knowledge. Pediatr Endocrinol Rev. 2015; 13: 512–20

23. Gerschultz KL et al. Extended cycling of combined hormonal contraceptives in adolescents:

physician views and prescribing practices. J Adolesc Health 2007; 40: 151–7

24. Stavroulis AI et al. Laparoscopic treatment of endometriosis in teenagers. Eur J Obstet Gynecol

Reprod Biol. 2006; 125: 248–50

25. Yeung P et al. Complete laparoscopic excision of endometriosis in teenagers: is postoperative

hormonal suppression necessary? Fertil Steril 2011; 95: 1909–12

26. Chapron C et al. Markers of adult endometriosis detectable in adolescence” J Pediatr Adoesc

Gynecol 2011; 24: 7–12

27. Hanssens S et al. Endometriosis in women under 25: a specific management? Minerva Med 2015;

106: 123–31

28. Tandoi I et al. High rate of endometriosis recurrence in young women. J Pediatr Adolesc Gynecol

2011; 24: 376–9

29. Ventolini G et al. Endometriosis in adolescence: A long-term follow-up fecundability assessment.

RBEJ 2005; 3: 1–4

30 Liu X et al. Patterns of and risk factors for recurrence in women with ovarian endometriomas.

Obstet Gynecol 2007, 109: 1411–20

31 Melin A et al. Endometriosis and the risk of cancer with special emphasis on ovarian cancer. Hum

Reprod 2006; 21: 1237–42

32 Zannoni L et al. Dysmenorrhea, absenteeism from school, and symptoms suspicious for

endometriosis in adolescents. J Pediatr Adolesc Gynecol 2014; 27: 258–65